Cargando…
Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of (68)Ga-, (205/206)Bi-, and (177)Lu-Labeled NAPamide-Based Radiopharmaceuticals
Although radiolabeled alpha-melanocyte stimulating hormone-analogue NAPamide derivatives are valuable melanoma-specific diagnostic probes, their rapid elimination kinetics and high renal uptake may preclude them from being used in clinical settings. We aimed at improving the pharmacokinetics of radi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536547/ https://www.ncbi.nlm.nih.gov/pubmed/37765089 http://dx.doi.org/10.3390/ph16091280 |
_version_ | 1785112892887007232 |
---|---|
author | Szücs, Dániel Szabó, Judit P. Arató, Viktória Gyuricza, Barbara Szikra, Dezső Tóth, Imre Képes, Zita Trencsényi, György Fekete, Anikó |
author_facet | Szücs, Dániel Szabó, Judit P. Arató, Viktória Gyuricza, Barbara Szikra, Dezső Tóth, Imre Képes, Zita Trencsényi, György Fekete, Anikó |
author_sort | Szücs, Dániel |
collection | PubMed |
description | Although radiolabeled alpha-melanocyte stimulating hormone-analogue NAPamide derivatives are valuable melanoma-specific diagnostic probes, their rapid elimination kinetics and high renal uptake may preclude them from being used in clinical settings. We aimed at improving the pharmacokinetics of radiolabeled DOTA-NAPamide compounds by incorporating a 4-(p-iodo-phenyl)-butanoic acid (IPB) into the molecules. Followed by (68)Ga-, (205/206)Bi-, and (177)Lu-labelling, the radiopharmaceuticals ([(68)Ga]Ga-DOTA-IPB-NAPamide, [(205/206)Bi]Bi-DOTA-IPB-NAPamide, [(177)Lu]Lu-DOTA-IPB-NAPamide) were characterized in vitro. To test the imaging behavior of the IPB-containing probes, B16F10 tumor-bearing C57BL/6 mice were subjected to in vivo microPET/microSPECT/CT imaging and ex vivo biodistribution studies. All tracers were stable in vitro, with radiochemical purity exceeding 98%. The use of albumin-binding moiety lengthened the in vivo biological half-life of the IPB-carrying radiopharmaceuticals, resulting in elevated tumor accumulation. Both [(68)Ga]Ga-DOTA-IPB-NAPamide (5.06 ± 1.08 %ID/g) and [(205/206)Bi]Bi-DOTA-IPB-NAPamide (4.50 ± 0.98 %ID/g) exhibited higher B16F10 tumor concentrations than their matches without the albumin-binding residue ([(68)Ga]Ga-DOTA-NAPamide and [(205/206)Bi]Bi-DOTA-NAPamide: 1.18 ± 0.27 %ID/g and 3.14 ± 0.32; respectively), however; the large amounts of off-target radioactivity do not confirm the benefits of half-life extension for short-lived isotopes. Enhanced [(177)Lu]Lu-DOTA-IPB-NAPamide tumor uptake even 24 h post-injection proved the advantage of IPB-based prolonged circulation time regarding long-lived radionuclides, although the significant background noise must be addressed in this case as well. |
format | Online Article Text |
id | pubmed-10536547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105365472023-09-29 Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of (68)Ga-, (205/206)Bi-, and (177)Lu-Labeled NAPamide-Based Radiopharmaceuticals Szücs, Dániel Szabó, Judit P. Arató, Viktória Gyuricza, Barbara Szikra, Dezső Tóth, Imre Képes, Zita Trencsényi, György Fekete, Anikó Pharmaceuticals (Basel) Article Although radiolabeled alpha-melanocyte stimulating hormone-analogue NAPamide derivatives are valuable melanoma-specific diagnostic probes, their rapid elimination kinetics and high renal uptake may preclude them from being used in clinical settings. We aimed at improving the pharmacokinetics of radiolabeled DOTA-NAPamide compounds by incorporating a 4-(p-iodo-phenyl)-butanoic acid (IPB) into the molecules. Followed by (68)Ga-, (205/206)Bi-, and (177)Lu-labelling, the radiopharmaceuticals ([(68)Ga]Ga-DOTA-IPB-NAPamide, [(205/206)Bi]Bi-DOTA-IPB-NAPamide, [(177)Lu]Lu-DOTA-IPB-NAPamide) were characterized in vitro. To test the imaging behavior of the IPB-containing probes, B16F10 tumor-bearing C57BL/6 mice were subjected to in vivo microPET/microSPECT/CT imaging and ex vivo biodistribution studies. All tracers were stable in vitro, with radiochemical purity exceeding 98%. The use of albumin-binding moiety lengthened the in vivo biological half-life of the IPB-carrying radiopharmaceuticals, resulting in elevated tumor accumulation. Both [(68)Ga]Ga-DOTA-IPB-NAPamide (5.06 ± 1.08 %ID/g) and [(205/206)Bi]Bi-DOTA-IPB-NAPamide (4.50 ± 0.98 %ID/g) exhibited higher B16F10 tumor concentrations than their matches without the albumin-binding residue ([(68)Ga]Ga-DOTA-NAPamide and [(205/206)Bi]Bi-DOTA-NAPamide: 1.18 ± 0.27 %ID/g and 3.14 ± 0.32; respectively), however; the large amounts of off-target radioactivity do not confirm the benefits of half-life extension for short-lived isotopes. Enhanced [(177)Lu]Lu-DOTA-IPB-NAPamide tumor uptake even 24 h post-injection proved the advantage of IPB-based prolonged circulation time regarding long-lived radionuclides, although the significant background noise must be addressed in this case as well. MDPI 2023-09-11 /pmc/articles/PMC10536547/ /pubmed/37765089 http://dx.doi.org/10.3390/ph16091280 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Szücs, Dániel Szabó, Judit P. Arató, Viktória Gyuricza, Barbara Szikra, Dezső Tóth, Imre Képes, Zita Trencsényi, György Fekete, Anikó Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of (68)Ga-, (205/206)Bi-, and (177)Lu-Labeled NAPamide-Based Radiopharmaceuticals |
title | Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of (68)Ga-, (205/206)Bi-, and (177)Lu-Labeled NAPamide-Based Radiopharmaceuticals |
title_full | Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of (68)Ga-, (205/206)Bi-, and (177)Lu-Labeled NAPamide-Based Radiopharmaceuticals |
title_fullStr | Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of (68)Ga-, (205/206)Bi-, and (177)Lu-Labeled NAPamide-Based Radiopharmaceuticals |
title_full_unstemmed | Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of (68)Ga-, (205/206)Bi-, and (177)Lu-Labeled NAPamide-Based Radiopharmaceuticals |
title_short | Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of (68)Ga-, (205/206)Bi-, and (177)Lu-Labeled NAPamide-Based Radiopharmaceuticals |
title_sort | investigation of the effect on the albumin binding moiety for the pharmacokinetic properties of (68)ga-, (205/206)bi-, and (177)lu-labeled napamide-based radiopharmaceuticals |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536547/ https://www.ncbi.nlm.nih.gov/pubmed/37765089 http://dx.doi.org/10.3390/ph16091280 |
work_keys_str_mv | AT szucsdaniel investigationoftheeffectonthealbuminbindingmoietyforthepharmacokineticpropertiesof68ga205206biand177lulabelednapamidebasedradiopharmaceuticals AT szabojuditp investigationoftheeffectonthealbuminbindingmoietyforthepharmacokineticpropertiesof68ga205206biand177lulabelednapamidebasedradiopharmaceuticals AT aratoviktoria investigationoftheeffectonthealbuminbindingmoietyforthepharmacokineticpropertiesof68ga205206biand177lulabelednapamidebasedradiopharmaceuticals AT gyuriczabarbara investigationoftheeffectonthealbuminbindingmoietyforthepharmacokineticpropertiesof68ga205206biand177lulabelednapamidebasedradiopharmaceuticals AT szikradezso investigationoftheeffectonthealbuminbindingmoietyforthepharmacokineticpropertiesof68ga205206biand177lulabelednapamidebasedradiopharmaceuticals AT tothimre investigationoftheeffectonthealbuminbindingmoietyforthepharmacokineticpropertiesof68ga205206biand177lulabelednapamidebasedradiopharmaceuticals AT kepeszita investigationoftheeffectonthealbuminbindingmoietyforthepharmacokineticpropertiesof68ga205206biand177lulabelednapamidebasedradiopharmaceuticals AT trencsenyigyorgy investigationoftheeffectonthealbuminbindingmoietyforthepharmacokineticpropertiesof68ga205206biand177lulabelednapamidebasedradiopharmaceuticals AT feketeaniko investigationoftheeffectonthealbuminbindingmoietyforthepharmacokineticpropertiesof68ga205206biand177lulabelednapamidebasedradiopharmaceuticals |